Go Pro
→ BlackRock and Vanguard already own THIS (From Monument Traders Alliance) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$32.40
-4.4%		$25.15
$10.83
▼
$41.14
$3.78B-0.133.64 million shs1.29 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$19.19
-5.5%		$24.77
$11.92
▼
$27.31
$3.79B1.082.33 million shs5.14 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$10.36
-5.6%		$11.33
$6.65
▼
$36.26
$961.16M1.98836,077 shs863,441 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$28.47
-2.0%		$29.13
$11.16
▼
$31.74
$3.70B0.811.09 million shs1.83 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-4.37%-6.06%+42.92%+132.93%+208.28%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-5.51%-23.67%-27.58%+6.91%+44.83%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-5.65%-4.34%-13.23%+6.26%+39.25%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-2.11%-5.06%-0.74%+21.83%+151.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$32.40
-4.4%		$25.15
$10.83
▼
$41.14
$3.78B-0.133.64 million shs1.29 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$19.19
-5.5%		$24.77
$11.92
▼
$27.31
$3.79B1.082.33 million shs5.14 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$10.36
-5.6%		$11.33
$6.65
▼
$36.26
$961.16M1.98836,077 shs863,441 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$28.47
-2.0%		$29.13
$11.16
▼
$31.74
$3.70B0.811.09 million shs1.83 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-4.37%-6.06%+42.92%+132.93%+208.28%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-5.51%-23.67%-27.58%+6.91%+44.83%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-5.65%-4.34%-13.23%+6.26%+39.25%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-2.11%-5.06%-0.74%+21.83%+151.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$36.5012.65% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.81
Moderate Buy$32.1767.62% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.77
Moderate Buy$42.40309.27% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.58
Moderate Buy$38.3034.54% Upside

Current Analyst Ratings Breakdown

Latest OLMA, AMLX, RCUS, and DYN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $36.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$30.00 ➝ $26.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$35.00 ➝ $30.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Underweight$17.00 ➝ $10.00
9/8/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$37.00
9/8/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00 ➝ $40.00
8/31/2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $57.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $55.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$28.00 ➝ $52.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $42.00
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M41.32N/AN/A$2.78 per share11.65
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$5.88 per shareN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$247M14.67N/AN/A$5.84 per share4.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$162.45M-$2.12N/AN/AN/AN/A-48.26%-43.04%11/9/2026 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$353M-$3.90N/AN/AN/A-393.16%-89.54%-45.61%10/27/2026 (Estimated)

Latest OLMA, AMLX, RCUS, and DYN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.5515-$0.61-$0.0585-$0.61N/AN/A
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/5/2026Q2 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.8912-$0.72+$0.1712-$0.72$21.98 million$41.00 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.023.14%N/AN/A N/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
0.01
8.86
8.86
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.22
3.82
3.82

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
12.56%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.42 million99.28 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100186.75 million169.08 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
7087.50 million76.51 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500127.33 million117.66 millionOptionable

Recent News About These Companies

Arcus Biosciences Announces New Employment Inducement Grants
September 9 at 4:35 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260909120397/en/arcus-biosciences-announces-new-employment-inducement-grants/
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4944552-arcus-biosciences-inc-rcus-presents-at-citigroups-biopharma-back-to-school-summit-2026
Allianz Asset Management GmbH Purchases New Stake in Arcus Biosciences, Inc. $RCUS
September 9 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-allianz-asset-management-gmbh-purchases-new-stake-in-arcus-biosciences-inc-rcus-2026-09-09/
42,338 Shares in Arcus Biosciences, Inc. $RCUS Acquired by Jupiter Topco LLC
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-42338-shares-in-arcus-biosciences-inc-rcus-acquired-by-jupiter-topco-llc-2026-09-05/
Arcus Biosciences Advances Casdatifan With New Liver Function Study
September 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/arcus-biosciences-advances-casdatifan-with-new-liver-function-study?utm_source=marketbeat.com&utm_medium=referral
The Manufacturers Life Insurance Company Makes New $1.41 Million Investment in Arcus Biosciences, Inc. $RCUS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-makes-new-141-million-investment-in-arcus-biosciences-inc-rcus-2026-09-04/
Legal & General Group Plc Invests $5.91 Million in Arcus Biosciences, Inc. $RCUS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-591-million-in-arcus-biosciences-inc-rcus-2026-09-04/
Corient Private Wealth LP Invests $1.82 Million in Arcus Biosciences, Inc. $RCUS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-invests-182-million-in-arcus-biosciences-inc-rcus-2026-09-04/
Arcus Biosciences, Inc. $RCUS Position Decreased by Montanova Capital LLC
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arcus-biosciences-inc-rcus-position-decreased-by-montanova-capital-llc-2026-09-01/
Wellington Management Group LLP Sells 194,068 Shares of Arcus Biosciences, Inc. $RCUS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-sells-194068-shares-of-arcus-biosciences-inc-rcus-2026-09-01/
Bank of New York Mellon Corp Invests $16.74 Million in Arcus Biosciences, Inc. $RCUS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-1674-million-in-arcus-biosciences-inc-rcus-2026-09-01/
Man Group plc Acquires New Shares in Arcus Biosciences, Inc. $RCUS
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-acquires-new-shares-in-arcus-biosciences-inc-rcus-2026-08-31/
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Arcus Biosciences, Inc. $RCUS
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-makes-new-investment-in-arcus-biosciences-inc-rcus-2026-08-27/
Deutsche Bank AG Invests $2.92 Million in Arcus Biosciences, Inc. $RCUS
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-invests-292-million-in-arcus-biosciences-inc-rcus-2026-08-27/
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
August 26, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260826011970/en/arcus-biosciences-to-participate-in-three-upcoming-investor-conferences/
Odyssean LLC Makes New Investment in Arcus Biosciences, Inc. $RCUS
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-odyssean-llc-makes-new-investment-in-arcus-biosciences-inc-rcus-2026-08-26/
PDT Partners LLC Buys New Stake in Arcus Biosciences, Inc. $RCUS
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pdt-partners-llc-buys-new-stake-in-arcus-biosciences-inc-rcus-2026-08-26/
Parkman Healthcare Partners LLC Purchases New Position in Arcus Biosciences, Inc. $RCUS
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-parkman-healthcare-partners-llc-purchases-new-position-in-arcus-biosciences-inc-rcus-2026-08-25/
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,827 Shares
August 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-rcus-insider-buying-and-selling-2026-08-25/
BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-50611-million-investment-in-arcus-biosciences-inc-rcus-2026-08-25/
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 2,827 Shares of Stock
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-arcus-biosciences-nyse-rcus-cao-sells-2827-shares-of-stock-2026-08-24/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
Desk with a monitor showing an upward stock price chart, printed financial reports, and a bronze bull statue.
3 Earnings Season Winners That Analysts Can't Stop Upgrading
By Dan Schmidt | September 7, 2026
Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$32.40 -1.48 (-4.37%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$32.13 -0.27 (-0.83%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$19.19 -1.12 (-5.51%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$19.26 +0.07 (+0.34%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$10.36 -0.62 (-5.65%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$10.22 -0.14 (-1.30%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$28.47 -0.59 (-2.04%)
Closing price 09/9/2026 03:59 PM Eastern
Extended Trading
$28.07 -0.40 (-1.41%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas